PT - 141
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) derived as an active metabolite of Melanotan II[1]. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women[2], bremelanotide enhances sexual desire by activating MC4R in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area[3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration using a practical dilution for clear insulin-syringe measurements.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once‑weekly regimen.
Goal: Support sexual desire and arousal through central melanocortin receptor activation
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 500–1500 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 500 mcg daily for the first 8 weeks to assess tolerance.
Escalate: Increase to 1000 mcg daily during Weeks 9–12.
Target: 1500 mcg daily during Weeks 13–16 if well tolerated.
Frequency: Once per day (subcutaneous).
Timing: Any consistent time; rotate injection sites between abdomen and thighs.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[9].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes (27–30G, 5/8-inch needle) for each injection; dispose in a sharps container[7].
Rotate injection sites (abdomen, thighs) on different days to avoid lipodystrophy or irritation[6].
Inject slowly; wait a few seconds before withdrawing the needle.
Nausea is the most common side effect and tends to be transient; flushing and headache may also occur[3].
Document daily dose and site rotation to maintain consistency.
How This Works
Bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R[3]. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire[3]. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue[3]. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning)[3][5].
Potential Benefits
Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo[3].
Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses and increasing arousal measures in women[1].
Adverse effects are usually mild and transient: most commonly nausea (~40%), flushing, headache, and injection-site reactions[3][5].
Transient increases in blood pressure have been reported; bremelanotide is not recommended for individuals with uncontrolled hypertension or cardiovascular disease[5][10].
Skin darkening (hyperpigmentation) may occur with repeated use due to peripheral MC1R activation and is generally reversible[3].
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Maintain a balanced diet and regular exercise routine to support overall hormonal health.
Prioritize sleep quality, as poor sleep can negatively affect libido and hormonal balance.
Manage stress through mindfulness, therapy, or relaxation techniques, as chronic stress can suppress sexual desire.
Limit alcohol consumption, which may dampen the effects of melanocortin receptor activation.
